Neuphoria Therapeutics (NEUP) EBITDA (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported EBITDA of -$347166.0 for Q1 2026, down 103.14% year-over-year from $11.1 million in Q1 2025, and down 114.26% on a QoQ basis from $2.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of EBITDA data on file, last reported at -$347166.0 in Q1 2026.
- Quarterly EBITDA fell 103.14% year-over-year to -$347166.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.6 million (down 402.78% YoY) and the FY2025 annual result came in at -$201103.0, up 98.7% from the prior year.
- EBITDA declined to -$347166.0 in Q1 2026 per NEUP's latest filing, from $2.4 million in the prior quarter.
- Across five years, EBITDA topped out at $11.1 million in Q1 2025 and bottomed at -$9.9 million in Q3 2025.
- The 4-year median for EBITDA is -$3.2 million (2024), against an average of -$2.1 million.
- Peak annual rise in EBITDA reached 431.32% in 2025, while the deepest fall reached 4392.71% in 2025.
- Tracing NEUP's EBITDA over 4 years: stood at -$4.1 million in 2023, then climbed by 21.24% to -$3.2 million in 2024, then surged by 175.34% to $2.4 million in 2025, then sank by 114.26% to -$347166.0 in 2026.
- Per Business Quant, the three latest NEUP EBITDA figures stand at -$347166.0 (Q1 2026), $2.4 million (Q4 2025), and -$9.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -347,166.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -347,166.00 |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | -9.86 Mn |
| Jun 30, 2025 | -7.82 Mn |
| Mar 31, 2025 | 11.07 Mn |
| Dec 31, 2024 | -3.23 Mn |
| Sep 30, 2024 | -219,406.00 |
| Jun 30, 2024 | -2.47 Mn |
| Mar 31, 2024 | -3.34 Mn |
| Dec 31, 2023 | -4.10 Mn |
| Sep 30, 2023 | -5.54 Mn |